Biallelic loss-of-function mutations in the SAMHD1 gene have been implicated in Aicardi-Goutières syndrome type 5 (AGS5), a paradigmatic example of type I interferon-mediated neuroinflammatory disorders predominantly targeting the central nervous system [1, 2]. This evidence concerns the gene SAMHD1 and Aicardi-Goutieres syndrome 5.